Mark Robert Baker, CEO at PROGENICS PHARMACEUTICALS INC (PGNX), bought 11,800 shares at $1.96 ($23K) on 2012-11-19, disclosed to the SEC on 2012-11-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| PGNX | BUY | 2013-01-23 | $3K | — | Filing → |
| PGNX | BUY | 2012-12-26 | $3K | — | Filing → |
| PGNX | BUY | 2012-11-30 | $3K | — | Filing → |